SCHEMBL2864220

SCHEMBL2864220

O=C(O)CCCCN(C(=O)Oc1ccc(Cl)cc1)c1ccc2nc(S)sc2c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 3/20 0.40
TMPRSS15 P98073 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX2 P34913 6/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CA2 P00918 1/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860633 0.89 TMPRSS15 (0.38) PPARDTMPRSS15MAPTALDH1A1POLB
SCHEMBL544323 0.89 EPHX2 (0.44) MAPTMEN1KMT2AEPHX2SMN1; SMN2
SCHEMBL2868103 0.88 PPARA (0.40) PPARDTMPRSS15MAPTPPARGPPARA
SCHEMBL2857711 0.88 TMPRSS15 (0.38) PPARDTMPRSS15
SCHEMBL2868489 0.87 CA2 (0.42) TMPRSS15TP53CA2
SCHEMBL2870349 0.86 TMPRSS15 (0.37) PPARDTMPRSS15KMT2ACA2
SCHEMBL2865978 0.85 TMPRSS15 (0.36) PPARDTMPRSS15ALDH1A1POLBTDP1
SCHEMBL2866937 0.84 TMPRSS15 (0.36) PPARDTMPRSS15EPHX2CA2
SCHEMBL2867200 0.83 TMPRSS15 (0.42) PPARDTMPRSS15PPARGPPARA
SCHEMBL3407795 0.83 PPARD (0.35) PPARDTMPRSS15MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-7709510-B2 Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-05-04 US claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 PPARD 1235/4885TMPRSS15 959/4885MAPT 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.